Clinical trial
A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer
NCT02350517 is registered in ClinicalTrials.gov with Yuhong Li as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer
- Lead sponsor
- Yuhong Li
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- December 31, 2022
- Enrollment
- 52 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.